PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.36−0.61 (-1.00%)
Close on Nov 17, 2026Market cap $5.04BP/E –Yield –
PTC Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
PTC Therapeutics's pe ratio was 8.4× on Apr 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 8.4× | −0.5 |
| 2025 | Dec 31, 2025 | 8.9× | – |
See a number that looks wrong?